The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) highlights the findings from the HOST IDEA trial investigating the non-inferiority of 3-6 months of DAPT compared to 12 months after percutaneous coronary intervention (PCI) using third-generation drug-eluting stents (DES) with ultrathin struts and advanced polymer technology.
The abstract entitled ‘Comparison Of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using The Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The Host-idea Randomized Clinical Trial‘ was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.
Interviews in this series:
Questions:
- What are the aims, design and eligibility criteria of the HOST IDEA study? (0:23)
- What were the primary and secondary endpoints and how well were they achieved? (2:23)
- What were the objectives and findings of the subgroup analyses? (5:32)
- How will these findings be used to inform future treatment decisions? (7:38)
Disclosures: Hyo-Soo Kim has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ACC 2023
Access more content on dual antiplatelet therapy
